Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant Nimotuzumab Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV

Trial Profile

Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant Nimotuzumab Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncoscience
  • Most Recent Events

    • 05 Jun 2012 Final results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 23 Sep 2011 Final results to be reported in the second half of 2011, after completion of a biomarker correlation study, according to a YM BioSciences media release
    • 08 Jun 2011 Additional lead trial centres added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top